List of Diagnostics Companies in Belgium - 8

Biocartis is a biotechnology company that specializes in innovative medical devices for precision medicine.

Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, who specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market. Eurogentec was founded in 1985. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. The life science BU specializes in Genomics (e.g. Lab scale to Large scale Oligonucleotides, PCR/qPCR Kits & Reagents and Assay Dispensing Service) and Proteomics (e.g. catalog and custom peptides & antibodies including a 28-Day Speedy protocol, assay kits and Proprietary Dyes & Quenchers). The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. The Biomanufacturing BU is a GMP Biomanufacturer specialized in the technology transfer, process development, scale-up and manufacturing of proteins, plasmids and vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements.

FLUIDDA’s main acitivities consist of developing imaging biomarkers to enhance drug development and patient care. These biomarkers combine biomedical imaging and advanced engineering methods. It has been demonstrated in recent studies that this novel approach yields sensitive outcome parameters to detect physiological or clinical changes in patients following an intervention. This provides additional insight into the mode of action of the intervention and allows for optimization of the therapy and improved patient selection. To support the implementation of this novel method into clinical studies and clinical practice, FLUIDDA also offers a CRO service with the focus on imaging. A complete package can therefore be offered to the client from initial protocol writing to full data analysis using the advanced processing techniques. To offer a high quality service FLUIDDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. #FRI #FunctionalRespiratoryImaging

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD). We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

IDS is a global medical diagnostics business dedicated to the development and provision of innovative automated and manual assays. Our development focus is in the clinical areas of bone and calcium metabolism, growth, hypertension and chronic kidney disease. Our IDS-iSYS system is designed with the flexibility to accommodate unique and challenging requirements, the IDS-iSYS automation brings testing efficiency and uncompromised quality to specialty immunoassay testing. IDS provides a compact bench top system that fully automates immunoassay testing. IDS has its global headquarters in the UK and has subsidiaries in Germany, France, Belgium, Italy and Nordic countries. Other markets, including key diagnostic markets of Spain, Australia, Japan are serviced by a network of highly qualified and experienced distributors within each territory.

miDiagnostics is using silicon chip technology which will bring miniaturized, rapid, easy-to-use, lab-quality tests with built-in connectivity direct to the patient and clinician. Combining a nanofluidic processor on a chip and a compact reader, miDiagnostics can measure virtually any biomarker from an easily accessed sample. The Company is developing an extensive portfolio of tests for screening, diagnosis and monitoring of a wide range of health conditions, including infectious diseases. Spun out of the world-leading R&D and innovation hub in nanoelectronics and digital technologies, imec, and a research collaboration with Johns Hopkins University, the leading US research and medical centre, miDiagnostics' goal is to enable fast, comprehensive and cost-effective health analysis, regardless of location. Based in Leuven, Belgium, miDiagnostics is a privately held company created in 2015.

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.

The world’s leading animal health company. Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. Community Guidelines: This page is intended for learning more about how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are some guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use